Prevalence of pregnant women with reactive HBsAg in Padang City in 2019
(1) Prodi Program Pendidikan Dokter Spesialis Obstetri dan Ginekologi Fakultas Kedokteran Universitas Andalas RSUP Dr. M. Djamil Padang
(2) Sub Division of Fetomaternal Medicine, Obstetrics and Gynecology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang, West Sumatera, Indonesia
(*) Corresponding Author
DOI: https://doi.org/10.25077/aoj.6.1.21-26.2022
Abstract
Introduction: Hepatitis B is an infectious disease that occurs in the liver caused by the hepatitis B virus (HBV). Transmission vertically 95% occurs in the perinatal period (during delivery) and 5% intra uterine. Hepatitis B infection can be acute to chronic. Chronic infection was defined as hepatitis B surface antigen (HBsAg) persistently in blood or serum for more than 6 months with or without active viral replication and evidence of hepatocellular injury or inflammation. Indonesia as a country with high endemicity of Hepatitis B is currently focusing on preventing mother to child transmission (PPIA) because 95% of hepatitis B transmission is vertical, namely from hepatitis B positive mothers to their babies. The number of pregnant women who have been tested for Hepatitis B using the HBsAg Rapid Diagnostic Test (RDT) in 2018 in Indonesia is still relatively small, which is only 39.95% of the target pregnant women who should be examined. In West Sumatra itself occupies the 30th position out of 34 provinces with the percentage of HBsAg reactive pregnant women as much as 0.97%.
Objective: This study aims to determine the incidence of pregnant women with reactive HBsAg in the city of Padang.
Methods: This research is a descriptive study. The data was taken from the recap of the number of pregnant women who were screened for hepatitis B in all public health centers in the city of Padang during 2019.
Result : There are 13,174 (72%) pregnant women who have been tested for HBsAg. Found 131 (0.95%) people with reactive HBsAg. The highest cases were found in the Lubuk Kilangan Public Health Center with 14 cases and the lowest in the opposite health center and Ulak Karang health center with 0 cases. The highest case finding occurred in June with 17 cases and the lowest in November with 7 cases.
Conclusion: The prevalence of pregnant women with reactive HBsAg was 0.95% in Padang City in 2019.
Keywords: Hepatitis B, HBsAg, Pregnant WomenFull Text:
PDFReferences
Infodatin. Siatuasi dan Analisis Hepatitis. Jakarta : Kementrian Kesehatan Republik Indpnesia; 2014.
WHO. Hepatitis B ; 2018.
Available at: https://www.who.int/news/room/factsheets/detail/hepatitis-b
Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018
Peraturan Menteri Kesehatan Republik Indonesia Nomor 52 Tahun 2017 tentang eliminasi penularan Human Immunodeficiency Virus, Sifilis, dan Hepatitis B dari ibu ke Anak.
Dinkes Provinsi Sumbar. Profil Kesehatan Provinsi Sumatera Barat 2016. Padang; Dinas Kesehatan Provinsi Sumatera Barat; 2018
Mustika S, Hasanah D. Prevalensi Infeksi Hepatitis B pada ibu Hamil di Malang. Jurnal Kedokteran Brawijaya. 2017; Vol 30 (1): 76-80.
Society for Maternal-Fetal Medicine (SMFM), Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016; 214(1):6-14.
Malekifar P, Babanejad M, Izadi N, Alavian SY. The Frequency of HbsAg in Pregnant Woman from Eastern Mediterranean and Middle Eastern Countries: A systematic Review and Meta-Analysis. Hepat Mon. 2018; 18(9).
Sheng Q, Wang S, Wu Y, et al. Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant woman in Shenyang, China. Medicine. 2018; 97:22.
Choisy M, Keomalaphet S, Xaydalasouk K, et al. Prevalence of Hepatitis V virus infection among pregnant women attending Antenatal Clinics in Vientiane, Laos, 2008-2014. Hindawi hepatitis research and treatment. 2017.
Muljono DH, Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian Journal of Hepato-gastroenterology. 2017; 7(1): 55-59.
Pawlowska M, Pniewska A, Pilarczyk M, Kozielewicz D, Domagalski K. Prophylaxis of vertical HBV infection. Expert Opin Drug Saf. 2016;15(10):1361-1368.
Tran TT. Hepatitis B in pregnancy. Clin Infect Dis. 2016; 62(Suppl. 4): S314‐S317.
Terrault NA et al. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018; 67(4)
Zhao Y, Chen YL, Song HQ, Huang PY, Wang LY, Liu W, Huang BK, Lv FP, Huang C, Yan B, Li XJ. Effects of maternal hepatitis B surface antigen positive status on the pregnancy outcomes: A retrospective study in Xiamen, China, 2011-2018. PLoS One. 2020 Mar 10;15(3):e0229732.
Pradipta R, Yanti RS. Prevalensi Kejadian Infeksi Virus HbsAg pada Bayi Baru Lahir dari Ibu dengan HbsAg positif. Indonesian Journal of Obstetrics & Gynecology Science. 2019; 2(2)Düzgüner S, Zengin T, Taşçı T, Turan T, Boran N, Tulunay G, Köse M. Long-term survival after total pelvic exenteration in a patient with recurrent cervical carcinoma: A case report. 2013, 186-188
Adesina O, Oladokun A, Akinyemi O, Adedokun B, Awolude O, Odaibo G, et al. Human immuno-deficiency virus and hepatitis B virus coinfection in pregnancy at the University College Hospital, Ibadan. Afr J Med Med Sci 2010;39:305–10. Ahizechukwu CE, Uzoamaka AE, Charles IO, Ifeanyichukwu UE, Chukwuanugo O. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol J 2011;8:12.
Buseri FI, Seiyaboh E, Jeremiah ZA. Surveying infections among pregnant women in the Niger Delta, Nigeria. J Glob Infect Dis 2010;2:203–11.
Chasela P, Wall E, Teshale M. Prevalence of HBV and occult HBV infections among pregnant women co-infected with HIV-1 in Lilongwe, Malawi: the Breast feeding, Antiretroviral and Nutrition (BAN) study. J Hepatol 2013;10–6.
Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis B in sub- Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900–9.
World Health Organization. WHO Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geneva: WHO; 2016 Available at: apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf. [Last accessed 25 February 2017].
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Address for Correspondence: